

## Referencias□

1. Lulich JP, O'Brien TD, Osborne CA, Polzin DJ. Feline renal failure: questions, answers, questions. *Compend Cont Ed Pract Vet* 1992; 14: 127-152
2. Dibartola SP, Rutgers HC, Zack PM, et al. Clinicopathologic findings associated with chronic renal disease in cats: 74 cases (1973-1984) *J Am Vet Med Assoc* 1987; 190:1196-1202
3. Elliott J, Barber PJ. Feline chronic renal failure: Clinical findings in 80 cases diagnosed between 1992 and 1995. *J Small Anim Pract* 1998;39:78-85
4. Bartges JW Chronic kidney disease in dogs and cats *Vet Clin Small Anim* 2012; 42: 669-692.
5. Langston CE, Eatroff AE. Chronic Kidney Disease. *Small Animal Critical Care Medicine*. 2<sup>nd</sup> ed. Saunders Elsevier, Missouri, US pp.661-666
6. IRIS - International Renal Interest Society ([www.iris-kidney.com](http://www.iris-kidney.com))
1. Mapleson WW. Effect of age on MAC in humans: a meta-analysis. *British Journal of Anaesthesia* 1996; 76:179-185.
2. Redondo JI, Suesta P, Gil L et al. Retrospective study of the prevalence of postanesthetic hypothermia in cats. *Vet Rec* 2012; 170(8):206.
3. Goldstein RE, Marks SL, Kass PH, et al. Gastrin concentrations in plasma of cats with chronic renal failure. *J Am Vet Med Assoc* 1998; 213: 826-828
4. Peters RM, Goldstein RE, Erb Hn, et al. Histopathologic features of canine uremic gastropathy: a retrospective study. *J Vet Intern Med* 2005;19:315-320
5. Ramsey I. *Small Animal Formulary*. 7<sup>th</sup> Edition. BSAVA; 2011.
6. Quimby JM, Gustafson DL, Lunn KF. The pharmacokinetics of mirtazapine in cats with chronic kidney disease and in age-matched control cats. *J Vet Intern Med* 2011;25:985-989
7. Houlihan DJ. Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine. *Ann Pharmacother* 2004; 38: 411-413
8. Silverstein DC, Santoro-Beer K. Daily intravenous fluid therapy. *Small Animal Critical Care Medicine* 2<sup>nd</sup> Ed. 2015 Saunders Elsevier, Missouri, US pp.316-321.
9. Elliott J, Syme HM, Reubens E et al. Assessment of acid-base status of cats with naturally occurring chronic renal failure. *J Small Anim Pract* 2003; 44:65-70.
10. Shahinfar S, Dickson T, Zhang Z et al. Baseline predictors of end-stage renal disease risk in patients with type 2 diabetes and nephropathy: new lessons from the RENAAL study. *Kidney Int* 2005; 67:S48-S51.
11. Syme HM, Markwell PJ, Pfeiffer D, Elliott J. Survival of cats with naturally occurring chronic renal failure is related to severity of proteinuria. *J Vet Intern Med* 2006;20:528-535
12. King JN, Gunn-Moore DA, Tasker S, Gleadhill A, Strehlau G, BENRIC ( BENazepril in Renal Insufficiency in Cats) study group. Tolerability and efficacy of benazepril in cats with chronic kidney disease. *J Vet Intern Med* 2006; 20:1054-1064.

13. Korman RM, White JD. Feline CKD. Current therapies- what is achievable? *J Feline Med Surg* 2013; 18:29-44.
14. Polzin DJ. Evidence-based step-wise approach to managing chronic kidney disease in dogs and cats. *J Vet Emerg Crit Care* 2013; 23:205-215.
15. Mizutani H, Koyama H, Watanabe T, Kitagawa H, Nakano M, Kajiwara K, King JN. Evaluation of the clinical efficacy of benazepril in the treatment of chronic renal insufficiency in cats. *J Vet Intern Med* 2006; 20:1074-1079.
16. Gowan RA, Lingard A, Johnston L, Stansen W, Brown S, Malik R. Retrospective case-control study on the effects of long-term dosing with meloxicam on renal function in aged cats with degenerative joint disease. *J Feline Med Surg* 2011; 13:752-761.
17. Gowan RA, Baral RM, Lingard AE, Catt MJ, Stansen W, Johnston L, Malik R. A retrospective analysis of the effects of meloxicam on the longevity of aged cats with and without overt chronic kidney disease. *J Feline Med Surg* 2012; 14:876-881.
18. Gunew MN, Menrath VH, Marshall RD. Long-term safety, efficacy and palatability of oral meloxicam at 0.01-0.03mg/kg for treatment of osteoarthritic pain in cats. *J Feline Med Surg* 2008; 10:235-241.
19. Flournoy WS, Wohl JS, Albrecht-Schmitt TJ, Schwartz DD. Pharmacologic identification of putative D1 dopamine receptors in feline kidneys. *J Vet Pharmacol Ther* 2003;26:283-290
20. Clark BJ. The role of dopamine in the periphery, In: Fluckiger E, Muller EE, Thorner MO. Eds. *The Dopaminergic System*. Heidelberg:Springer Sandoz; 1985, pp.27-39.
21. Wohl JS, Schwartz DD, Flournoy WS, Clark TP, Wright JC. Renal hemodynamic and diuretic effects of low-dosage dopamine in anesthetized cats. *J Vet Emerg Crit Care* 2007; 17:45-52.
22. Wasserman K, Huss R, Kullman R. Dopamine-induced diuresis in the cat without changes in renal haemodynamics. *Naunyn Schmiedebergs Arch Pharmacol* 1980; 312:77-83.
23. Clark KL, Robertson MJ, Drew GM. Do renal tubular dopamine receptors mediate dopamine-induced diuresis in the anesthetized cat? *J Cardiovasc Pharmacol* 1991;17:267-276
24. Schaer GL, Fink MP, Parrillo JE. Norepinephrine plus low-dose dopamine: Enhanced renal blood flow with combination pressor therapy. *Crit Care Med* 1985; 13:492-496.
25. Schetz M. Vasopressors and the kidney. *Blood Purif* 2002; 20:243-251.
26. Kidder AC, Chew D. Treatment options for hyperphosphatemia in feline CKD: What's out there? *J Feline Med Surg* 2009; 11:913-924.
27. Chalhoub S, Langston C, Eatroff A. Anemia of renal disease: what it is, what to do and what's new. *J Feline Med Surg* 2011;13:629-640
28. Gibson GR, Callan MB, Hoffman V, Giger U. Use of a hemoglobin-based oxygen-carrying solution in cats: 72 cases (1998-2000) *J Am Vet Med Assoc* 2002;221:96-102)

29. Kallan MB, Rentko VT. Clinical application of a hemoglobin-based oxygen-carrying solution. *Vet Clin Small Anim* 2003;33:1277-1293
30. Wehausen CE, Kirby R, Rudloff E. Evaluation of the effects of bovine hemoglobin glutamer-200 on systolic arterial blood pressure in hypotensive cats: 44 cases (1997-2008). *Am J Vet Med Assoc* 2001; 238:909-914.
31. Weingart C, Kohn B. Clinical use of a haemoglobin-based oxygen carrying solution (Oxyglobin®) in 48 cats (2002-2006) *J Feline Med Surg* 2008;10:431-438.
32. Bartges JW, Willis AM, Polzin DJ. Hypertension and renal disease. *Vet Clin North Am Small Anim Pract* 1996; 26:1331-1345.
33. Steele J, Henik R, Stepien R. Effects of angiotensin-converting enzyme inhibitor on plasma aldosterone concentration, plasma renin activity, and blood pressure in spontaneously hypertensive cats with chronic renal disease. *Vet Ther* 2002;3:157-166
34. Jepson RE, Syme HM, Elliot J. Plasma renin activity and aldosterone concentrations in hypertensive cats with and without azotaemia and in response to treatment with amlodipine besylate. *J Vet Intern Med* 2014;28:144-153
35. Popovic NA, Mullane JF, Yhap EO. Effects of acetylpromazine maleate on certain cardiorespiratory responses in dogs. *Am J Vet Res* 1972;33:1819-1824
36. Pypendop BH, Verstegen JP. Hemodynamic effects of medetomidine in the dog: A dose titration study. *Vet Surg* 1998;27:621-622
37. Murahata, Y., Hikasa, Y. (2012) Comparison of the diuretic effects of medetomidine hydrochloride and xylazine hydrochloride in healthy cats. *Am J Vet Res* 73, 1871-1880
38. Talukdar, H., Hikasa, Y. (2009) Diuretic effects of medetomidine compared with xylazine in healthy dogs. *Can J Vet Res* 73, 224-236.
39. Robinson R, Borer-Weir K. The effects of diazepam or midazolam on the dose of propofol required to induce anaesthesia in cats. *Vet Anaesth Analg* 2015 doi:10.1111/vaa.12244
40. Child KJ, Davis B, Dodds MG et al. Anesthetic, cardiovascular and respiratory effects of a new steroidal agent CT 1341: A comparison with other intravenous anaesthetic drugs in the unrestrained cat. *British Journal of Pharmacology* 1972; 46:189-200.
41. Chang T, Glazko AJ. Biotransformation and disposition of ketamine. *International Anesthesiology Clinics*. 1974; 12:157-177.
42. Muir W, Lerche P, Wiese A, Nelson L, Pasloske K, Whittem T. The cardiorespiratory and anesthetic effects of clinical and supraclinical doses of alfaxalone in cats. *Vet Anaesth Analg* 2009; 36:42-54.
43. Maney JK, Shepard MK, Braun C, Cremer J, Hofmeister EH. A comparison of cardiopulmonary and anesthetic effects of an induction dose of alfaxalone or propofol in dogs. *Vet Anaesth Analg* 2013; 40:237-244.
44. Ferreira TH, Steffey EP, Mama KR, Rezende ML, Aguiar AJA. Determination of the sevoflurane sparing effect of methadone in cats. *Vet Analg Anaesth* 2011; 38:310-319.

45. Robertson SA, Taylor PM. Pain management in cats- past, present and future. Part 2. Treatment of pain-clinical pharmacology. *J Feline Med Surg* 2004; 6:321-333.
46. Steagall PV, Carnicelli P, Taylor PM, Luna SP, Dixon M, Ferreira TH. Effects of subcutaneous methadone, morphine, buprenorphine or saline on thermal and pressure thresholds in cats. *J Vet Pharmacol Ther* 2006; 29:531-537.
47. Murrell J. Clinical use of opioids in dogs and cats. Part 1 and 2. (a) *Companion Animal* 2011;16:35-38, 44-49.
48. Murrell, J. Clinical use of methadone in cats and dogs. (b) *Companion Animal* 2011; 16:56-61.
49. Bortolami E, Love EJ. Practical use of opioids in cats: a state-of-the-art, evidence-based review. *J Feline Med Surg* 2015; 17:283-311.
50. Warne LN, Beths T, Holm M, Bauquier SH. Comparison of perioperative analgesic efficacy between methadone and butorphanol in cats. *J Am Vet Med Assoc* 2013; 243:844-850.
51. Pypendop BH, Ilkiw JE. Assessment of the hemodynamic effects of lidocaine administered IV in isoflurane anesthetized cats. *Am J Vet Res* 2005; 66:661-668
52. Pypendop BH, Ilkiw JE, Robertson SA. Effects of intravenous administration of lidocaine on the thermal threshold in cats. *Am J Vet Res* 2006;67:16-20
53. Winter MD, Miles KG, Riedesel DH. Effect of sedation protocol on glomerular filtration rate in cats as determined by use of quantitative renal scintigraphy. *Am J Vet Res* 2011; 72:1222-1225
54. Thornhill J, Cechner P. Traumatic injuries to the kidney, ureter, bladder, and urethra. *Vet Clin North Am Small Anim Pract* 1981; 11(1):157-169.
55. Rieser T. Urinary tract emergencies. *Vet Clin North Am Small Anim Pract* 2005; 35(2):359-373.
56. Lanz O, Waldron D. Renal and ureteral surgery in dogs. *Clin Tech Small Anim Pract* 2000; 15(1):1-10.
57. Aumann M, Worth L, Drobatz K. Uroperitoneum in cats: 26 cases (1986-1995). *J Am Anim Hosp Assoc* 1998; 34(4):315-324.
58. Corriere JJ, Sandler C. Management of the ruptured bladder: seven years of experience with 111 cases. *J Trauma* 1986; 26(9): 830-833.
59. Ettinger P, Regan T, Oldewurtel H. Hyperkalemia, cardiac conduction, and the electrocardiogram: a review. *Am Heart J* 1974; 88(3):360-371.
60. Osborne C, Finco D. Urinary tract emergencies and renal care following trauma. *Vet Clin North Am Small Anim Pract* 1972; 2(2):259-292.
61. Tag T, Day T. Electrocardiographic assessment of hyperkalemia in dogs and cats. *J Vet Emerg Crit Care* 2008; 18(1):61-67.

62. Burrows C, Bovee K. Metabolic changes due to experimentally induced rupture of the canine urinary bladder. *Am J Vet Res* 1974; 35(8):1083–1088.
63. Lee J, Drobatz K. Characterization of the clinical characteristics, electrolytes, acid-base, and renal parameters in male cats with urethral obstruction. *J Vet Emerg Crit Care* 2003; 13(4):227–233.
64. Schmiedt C, Tobias K, Otto C. Evaluation of abdominal fluid: peripheral blood creatinine and potassium ratios for diagnosis of uroperitoneum in dogs. *J Vet Emerg Crit Care* 2001; 11(4): 275–280.
65. Hamilton M, Sissener T, Baines S. Traumatic bilateral ureteric rupture in two dogs. *J Small Anim Pract* 2006; 47(12):737–740.
66. Fossum T. *Small Animal Surgery*, 3rd ed. St. Louis: Mosby Elsevier; 2007, pp. 678–681.
67. Ross L, Labato M. Peritoneal dialysis, In: DiBartola S. ed. *Fluid, Electrolyte, and Acid-base Disorders in Small Animal Practice*, 3<sup>rd</sup> ed. St. Louis: Saunders Elsevier; 2006, pp. 636–637.
68. Drobatz K, Cole S. The influence of crystalloid type on acid-base and electrolyte status of cats with urethral obstruction. *J Vet Emerg Crit Care* 2008; 18(4):355–361.